Patent · US Active

Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereof

US11891435B2 · kind B2 · utility

0Cited by

16References

24Claims

0Family size

Assignee

AMGEN INC. · US

Inventors

Neeraj Jagdish Agrawal · Thousand Oaks, US
Kevin Graham · Thousand Oaks, US
Agnes Eva Hamburger · Newbury Park, US
Christopher MOHR · Newbury Park, US
Derek E. Piper · Santa Clara, US
Kenneth W. Walker · Newbury Park, US
Zhulun Wang · Palo Alto, US
Cen Xu · Newbury Park, US

Key dates

Filing date	Dec 21, 2021
Grant date	Feb 6, 2024
Priority date	—
Expiry date	Dec 21, 2041

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.